Subscribe
Logo small
Search

AOTMiT: The Transparency Council will evaluate drugs for lung cancer, cervical cancer and plasmocytic myeloma, among others.

MedExpress Team

medexpress.pl

Published Nov. 22, 2024 07:41

AOTMiT: The Transparency Council will evaluate drugs for lung cancer, cervical cancer and plasmocytic myeloma, among others. - Header image
Źródło: AOTMiT
The next meeting of the Transparency Council will be held on Monday, November 25.

The agenda includes:

1 Prepare a position paper on the evaluation of the drug Talvey (talquetamabum) under drug program B.54. "Treatment of patients with plasmocytic myeloma" (ICD-10: C90.0).

2 Prepare a position paper on the evaluation of the drug Libtayo (cemiplimabum) under the drug program B.6. "Treatment of patients with lung cancer (ICD-10: C34) and pleural mesothelioma (ICD-10: C45)".

3 Prepare a position paper on the evaluation of the drug Libtayo (cemiplimabum) under drug program B.159. "Treatment of patients with cervical cancer (ICD-10: C53)".

4 Prepare a position paper on the evaluation of the drug Tavneos (avacopanum) under drug program B.75. "Treatment o...

Content locked

To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].

If you already have an account, please log in

Szukaj nowych pracowników

Dodaj ogłoszenie o pracę za darmo

Lub znajdź wyjątkowe miejsce pracy!

Read also